Cost effectiveness of pharmacotherapies in early Parkinson's disease.
Parkinson's disease is one of the most common chronic neurodegenerative diseases. The progression of disease and the psychosocial consequences exert a major impact on patients' health-related quality of life. Although levodopa provides the best symptomatic benefit with the fewest short-term adverse effects, long-term treatment results in motor complications that are associated with both higher costs and considerable increase in patients' discomfort. The introduction of dopamine agonists early in the treatment of Parkinson's disease leads to a delay of these motor complications, but the treatment is associated with higher costs.In this review we evaluate available cost-effectiveness analyses of the dopamine agonists pramipexole, pergolide, bromocriptine, ropinirole, cabergoline and levodopa in the treatment of early Parkinson's disease. Considerable methodological differences in the identified studies complicate a comparison and impede clear evidence as to which dopamine agonist treatment is the most cost effective in early Parkinson's disease. Novel head-to-head comparisons considering the actual treatment guidelines are necessary to identify the most cost-effective alternative in treating de novo Parkinson's disease patients.
Eggert
Karla M
KM
Department of Neurology, Philipps-University Marburg, Marburg, Germany.
Reese
Jens P
JP
Oertel
Wolfgang H
WH
Dodel
Richard
R
D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics*
D000978:Antiparkinson Agents
Arch Neurol. 2002 Dec;59(12):1937-43
12470183
Eur J Health Econ. 2004 Oct;5 Suppl 1:S63-6
15754076
Mov Disord. 2007 Aug 15;22(11):1528-37
17523198
Drugs Aging. 2006;23(9):693-721
17020395
Pharmacoeconomics. 2005;23(12):1257-70
16336019
Eur J Neurol. 2005 Jun;12 Suppl 1:68-73
15877783
Med Care. 2005 Jul;43(7 Suppl):5-14
16056003
Arch Gen Psychiatry. 1961 Jun;4:561-71
13688369
Pharmacoeconomics. 2006;24(11):1069-78
17067192
Ann Neurol. 2001 Mar;49(3):298-303
11261503
Lancet. 2002 Aug 31;360(9334):711-5
12241891
Arch Neurol. 2004 Jul;61(7):1044-53
15262734
Parkinsonism Relat Disord. 2005 Jun;11(4):221-6
15878582
J Neurol. 1998 May;245 Suppl 1:S10-4
9617716
Pharmacoeconomics. 2003;21(2):115-27
12515573
Qual Life Res. 1995 Jun;4(3):241-8
7613534
Neurology. 1967 May;17(5):427-42
6067254
Pharmacoeconomics. 2001;19(10):1013-38
11735671
Mov Disord. 2003 Jun;18(6):637-45
12784266
Pharmacoeconomics. 2005;23(8):817-36
16097843
Ann Neurol. 1984 Sep;16(3):278-82
6333204
Expert Rev Neurother. 2004 Nov;4(6):985-93
15853525
Pharmacoeconomics. 1998 Sep;14(3):299-312
10186468
Pharmacoeconomics. 2001;19(8):875-86
11596839
Med Decis Making. 2007 May-Jun;27(3):327-34
17502449
Eur J Neurol. 2005 Dec;12(12):956-63
16324089
Parkinsonism Relat Disord. 2003 Jun;9(5):301-7
12781598
Mov Disord. 2007 Jul 30;22(10):1390-1401
17516489
BMJ. 1992 Jul 18;305(6846):160-4
1285753
N Engl J Med. 2007 Jan 4;356(1):29-38
17202453
Ann Neurol. 1986 Apr;19(4):365-72
3707088
Med Decis Making. 2004 Sep-Oct;24(5):472-85
15358996
Nervenarzt. 2006 Oct;77(10):1204-9
17004081
Qual Life Res. 1996 Apr;5(2):195-204
8998488
Neurologia. 1999 Aug-Sep;14(7):338-43
10570620
Stat Methods Med Res. 2002 Dec;11(6):455-68
12516984
Pharmacoeconomics. 2005;23(6):529-36
15960550
Pharmacoeconomics. 2006;24(11):1043-53
17067190
Mov Disord. 2005 Nov;20(11):1449-54
16007641
Health Policy. 1992 Jul;21(3):249-79
10120196
Mov Disord. 1993 Oct;8(4):466-72
8232356
N Engl J Med. 2000 May 18;342(20):1484-91
10816186
Mov Disord. 2003 Dec;18(12):1455-8
14673881
Mov Disord. 2003 Oct;18(10):1139-45
14534917
Drugs. 1998;55 Suppl 1:23-30
9483167
Mov Disord. 2000 May;15(3):439-45
10830407
Mov Disord. 2007 Jan;22(1):41-7
17115387
Mov Disord. 2006 Nov;21(11):1844-50
16958094
Mov Disord. 2002 Jan;17(1):60-7
11835440
N Engl J Med. 1989 Nov 16;321(20):1364-71
2509910
Arch Neurol. 1987 Oct;44(10):1013-6
3632372
Eur J Neurol. 2006 Nov;13(11):1170-85
17038031
J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4
8676165
Clin Neuropharmacol. 1994;17 Suppl 2:S32-44
9358193
Parkinsonism Relat Disord. 2003 Jan;9(3):163-8
12573872
Pharmacoeconomics. 2001;19(7):729-52
11548910
Value Health. 2004 Sep-Oct;7(5):610-26
15367256
Mov Disord. 2006 Mar;21(3):343-53
16211594
N Engl J Med. 2006 Aug 31;355(9):896-908
16943402
Pharmacoeconomics. 2005;23(5):449-59
15896097
Mov Disord. 2003 Aug;18(8):898-905
12889079
Value Health. 2001 Jul-Aug;4(4):308-15
11705298
J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73
10864606
Neuroepidemiology. 2000 Mar-Apr;19(2):100-8
10686534
Pharmacoeconomics. 1998 Nov;14(5):541-57
10344917
Value Health. 2003 Jan-Feb;6(1):9-17
12535234
Mov Disord. 2003 Jul;18(7):773-83
12815656
Neurology. 2002 Jul 9;59(1):103-8
12105315
Health Econ. 1994 Mar-Apr;3(2):95-104
8044216
J Geriatr Psychiatry Neurol. 1992 Jul-Sep;5(3):142-8
1497791
Eur J Health Econ. 2003;4(1):37-42
15609167
Parkinsonism Relat Disord. 2004 Dec;10(8):493-9
15542010
Health Policy. 1990 Dec;16(3):199-208
10109801
Mov Disord. 2004 Sep;19(9):1020-8
15372591
Parkinsonism Relat Disord. 2007 Mar;13(2):108-14
17055326
Pharmacoeconomics. 1999 Jul;16(1):59-69
10539122
Mov Disord. 2002 Nov;17(6):1213-20
12465059
Age Ageing. 1997 Sep;26(5):353-7
9351479
Eur J Health Econ. 2003 Sep;4(3):222-31
15609189
Value Health. 2005 Sep-Oct;8(5):521-33
16176491
Mov Disord. 2002 Sep;17(5):867-76
12360535
Parkinsonism Relat Disord. 2003 Jun;9(5):291-4
12781596
Mov Disord. 2000 Nov;15(6):1112-8
11104193